West Pharmaceutical Services (WST) Operating Leases (2019 - 2026)

West Pharmaceutical Services has disclosed Operating Leases across 8 years of filings, most recently posting $113.4 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $113.4 million, up 12.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $113.4 million (up 12.72% YoY), and the FY2025 annual result was $95.6 million, up 16.87% from the prior year.
• Operating Leases came in at $113.4 million for Q1 2026 at West Pharmaceutical Services, up from $95.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $113.4 million in Q1 2026 to a low of $77.2 million in Q3 2022.
• The 5-year median for Operating Leases is $87.3 million (2023), against an average of $90.9 million.
• Across the five-year window, Operating Leases surged 47.62% in 2022 and slipped 9.14% in 2023, its largest moves.
• West Pharmaceutical Services' Operating Leases stood at $93.0 million in 2022, then slipped by 9.14% to $84.5 million in 2023, then decreased by 3.2% to $81.8 million in 2024, then rose by 16.87% to $95.6 million in 2025, then rose by 18.62% to $113.4 million in 2026.
• The last three Operating Leases figures came in at $113.4 million (Q1 2026), $95.6 million (Q4 2025), and $94.9 million (Q3 2025), per Business Quant data.